Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2020-11-24
Target enrollment:
Participant gender:
Summary
The purpose of this research is to estimate the effectiveness of a response adapted approach
with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed
standard risk multiple myeloma. This means that participants will be given the study drug,
lenalidomide but depending on how they respond to this drug they may also be given
dexamethasone and/or prednisone to help with their treatment.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute